Gapping down
In reaction to earnings/guidance:
- DORM -4.4%, PHG -3.3%, PKX -2.5%
Other news:
- TCDA -93.4% (announces VALOR-CKD trial did not meet primary endpoint)
- YUMC -10.4% (announces primary listing on the Hong Kong Stock Exchange and inclusion in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect)
- AXDX -8.8% (discloses that the FDA clarified that company must obtain 510(k) clearance to continue marketing and distribute Accelerate Arc Products in U.S.)
- PINE -2.9% (entered into separate equity distribution agreements having an aggregate gross sales price of up to $150,000,000)
- HA -2.9% (discloses select financial statements should no longer be relied upon)
- VRDN -2.8% (Presents Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial)
- TSLA -2.3% (discloses that YTD it recorded $170 million of impairment losses resulting from changes to the carrying value of its bitcoin and gains of $64 million on certain conversions of bitcoin into fiat currency)
- HZNP -1.9% (reports New Real-World Analysis of TEPEZZA)
- NVCR -1.3% (Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting)
Analyst comments:
- AAN -3.4% (downgraded to Underperform from Neutral at BofA Securities)
- ADI -1.6% (downgraded to Equal Weight from Overweight at Barclays)
- META -0.7% (downgraded to Neutral from Buy at BofA Securities)